---
title: "Silexion net loss widens 44% to USD 3.6 million in Q2 FY26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295936819.md"
description: "Silexion Therapeutics reported a Q2 FY26 net loss of USD 3.6 million, widening 44% year-over-year due to increased R&D expenses of USD 2.2 million. Cash reserves dropped to USD 2.2 million from USD 6 million at year-end. The company closed a registered public offering on August 13 for approximately USD 2.5 million to maintain Nasdaq compliance. Additionally, its drug SIL204 entered an active Phase 2/3 trial for locally advanced pancreatic cancer."
datetime: "2026-08-14T12:45:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295936819.md)
  - [en](https://longbridge.com/en/news/295936819.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295936819.md)
generator: "portal-rs"
---

# Silexion net loss widens 44% to USD 3.6 million in Q2 FY26

-   Silexion posted a Q2 net loss of USD 3.6 million, widening 44% year over year, as R&D climbed to USD 2.2 million. \* G&A rose 15.4% to USD 1.5 million, while financial results swung to net income of about USD 100,000. \* Cash and cash equivalents fell to USD 2.2 million at June 30 from USD 6 million at Dec. 31. \* SIL204 entered an active Phase 2⁄3 trial in locally advanced pancreatic cancer, with the first site initiated at Tel Aviv Sourasky Medical Center in July. \* Management said a registered public offering closed Aug. 13 with gross proceeds of about USD 2.5 million, supporting Nasdaq listing compliance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140845PRIMZONEFULLFEED1001257668) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | SLXN Stock News](https://longbridge.com/en/news/295937580.md)
- [Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center](https://longbridge.com/en/news/294201019.md)
- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Granite-Integral co-leads $34 million Series D financing in Craif](https://longbridge.com/en/news/296226716.md)
- [RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers](https://longbridge.com/en/news/296039942.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**